Bodei L, Herrmann K, Schöder H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19:534–50.
Article CAS PubMed PubMed Central Google Scholar
Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: making precision medicine possible. CA Cancer J Clin. 2023;73:255–74.
Pomykala KL, Hadaschik BA, Sartor O, Gillessen S, Sweeney CJ, Maughan T, Hofman MS, Herrmann K. Next generation radiotheranostics promoting precision medicine. Ann Oncol. 2023;34:507–19.
Article CAS PubMed Google Scholar
Simeon R, Chen Z. In vitro-engineered non-antibody protein therapeutics. Protein Cell. 2018;9(1):3–14.
Article CAS PubMed Google Scholar
Vadevoo SMP, Gurung S, Lee HS, Gunassekaran GR, Lee SM, Yoon JW, Lee YK, Lee B. Peptides as multifunctional players in cancer therapy. Exp Mol Med. 2023;55:1099–109.
Article CAS PubMed PubMed Central Google Scholar
Ståhl S, Gräslund T, Eriksson Karlström A, Frejd FY, Nygren PÅ, Löfblom J. Affibody molecules in Biotechnological and Medical Applications. Trends Biotechnol. 2017;35:691–712.
Tolmachev V, Orlova A. Affibody molecules as Targeting vectors for PET imaging. Cancers. 2020;12:651.
Article CAS PubMed PubMed Central Google Scholar
Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, Nilsson FY. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006;66:4339–48.
Article CAS PubMed Google Scholar
Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34:157–64.
Article CAS PubMed PubMed Central Google Scholar
Sörensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, Orlova A, Sandström M, Lubberink M, Olofsson H, Carlsson J, Lindman H. Measuring HER2-Receptor expression in metastatic breast Cancer using [68Ga]ABY-025 affibody PET/CT. Theranostics. 2016;6:262–71.
Article PubMed PubMed Central Google Scholar
Zhou N, Liu C, Guo X, Xu Y, Gong J, Qi C, Zhang X, Yang M, Zhu H, Shen L, Yang Z. Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. Eur J Nucl Med Mol Imaging. 2021;48:161–75.
Article CAS PubMed Google Scholar
Miao H, Sun Y, Jin Y, Hu X, Song S, Zhang J. Application of a Novel 68Ga-HER2 Affibody PET/CT imaging in breast Cancer patients. Front Oncol. 2022;12:894767.
Article PubMed PubMed Central Google Scholar
Alhuseinalkhudhur A, Lindman H, Liss P, Sundin T, Frejd FY, Hartman J, Iyer V, Feldwisch J, Lubberink M, Rönnlund C, Tolmachev V, Velikyan I, Sörensen J. Human epidermal growth factor receptor 2-Targeting [68Ga]Ga-ABY-025 PET/CT predicts early metabolic response in metastatic breast Cancer. J Nucl Med. 2023;64:1364–70.
Article CAS PubMed PubMed Central Google Scholar
Liu J, Guo X, Wen L, Wang L, Liu F, Song G, Zhu H, Zhou N, Yang Z. Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients. Eur J Nucl Med Mol Imaging. 2023;50:2775–86.
Article CAS PubMed Google Scholar
Bragina O, Chernov V, Larkina M, Rybina A, Zelchan R, Garbukov E, Oroujeni M, Loftenius A, Orlova A, Sörensen J, Frejd FY, Tolmachev V. Phase I clinical evaluation of 99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer. Theranostics. 2023;13:4858–71.
Article CAS PubMed PubMed Central Google Scholar
Garousi J, Vorobyeva A, Altai M. Influence of several compounds and drugs on the renal uptake of Radiolabeled Affibody Molecules. Molecules. 2020;25:2673.
Article CAS PubMed PubMed Central Google Scholar
Altai M, Perols A, Tsourma M, Mitran B, Honarvar H, Robillard M, Rossin R, ten Hoeve W, Lubberink M, Orlova A, Karlström AE, Tolmachev V. Feasibility of Affibody-based Bioorthogonal Chemistry-mediated Radionuclide Pretargeting. J Nucl Med. 2016;57:431–6.
Article CAS PubMed Google Scholar
Oroujeni M, Tano H, Vorobyeva A, Liu Y, Vorontsova O, Xu T, Westerlund K, Orlova A, Tolmachev V, Karlström AE. Affibody-mediated PNA-Based Pretargeted Cotreatment improves survival of Trastuzumab-treated mice bearing HER2-Expressing xenografts. J Nucl Med. 2022;63:1046–51.
Article CAS PubMed PubMed Central Google Scholar
Liu Y, Vorobyeva A, Orlova A, Konijnenberg MW, Xu T, Bragina O, Loftenius A, Rosander E, Frejd FY, Tolmachev V. Experimental therapy of HER2-Expressing xenografts using the second-generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071. Pharmaceutics. 2022;14:1092.
Article CAS PubMed PubMed Central Google Scholar
Tolmachev V, Mume E, Sjöberg S, Frejd FY, Orlova A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur J Nucl Med Mol Imaging. 2009;36:692–701.
Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, Sandström M, Rosik D, Carlsson J, Lundqvist H, Wennborg A, Nilsson FY. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007;67:2773–82.
Article CAS PubMed Google Scholar
Orlova A, Jonsson A, Rosik D, Lundqvist H, Lindborg M, Abrahmsen L, Ekblad C, Frejd FY, Tolmachev V. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein. J Nucl Med. 2013;54(6):961–8.
Article CAS PubMed Google Scholar
Jonsson A, Dogan J, Herne N, Abrahmsén L, Nygren PA. Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng Des Sel. 2008;21:515–27.
Article CAS PubMed Google Scholar
Liu Y, Xu T, Vorobyeva A, Loftenius A, Bodenko V, Orlova A, Frejd FY, Tolmachev V. Radionuclide Therapy of HER2-Expressing xenografts using [177Lu]Lu-ABY-027 Affibody Molecule alone and in combination with Trastuzumab. Cancers (Basel). 2023;15:2409.
Article CAS PubMed Google Scholar
Liu Y, Güler R, Liao Y, Vorobyeva A, Widmark O, Meuleman TJ, van den Koijen A, Naasz R, Bodenko V, Orlova A, Ekblad C, Tolmachev V, Frejd FY. Biologic evaluation of a heterodimeric HER2-Albumin targeted Affibody Molecule produced by chemo-enzymatic peptide synthesis. Pharmaceutics. 2022;14:2519.
Article CAS PubMed PubMed Central Google Scholar
Liu Y, Vorobyeva A, Xu T, Orlova A, Loftenius A, Bengtsson T, Jonasson P, Tolmachev V, Frejd FY. Comparative preclinical evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: impact of DOTA position on ABD Domain. Pharmaceutics. 2021;13:839.
Article CAS PubMed PubMed Central Google Scholar
Chen S, Li B, Xie H, Xu L, Niu G, Fan K, Fan Q. Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma. Cancer Biother Radiopharm. 2004;19:589–600.
Article CAS PubMed Google Scholar
Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, Oosterwijk E. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol. 1997;15:1529–37.
留言 (0)